Skip to content

SPECT-CT vs MRI for the Diagnosis of Osteoarthritis in the Foot and Ankle

SPECT-CT Versus MRI for the Diagnosis of Symptomatic Osteoarthritis in the Ankle, Hind- and Midfoot.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05912153
Enrollment
132
Registered
2023-06-22
Start date
2023-07-04
Completion date
2027-12-01
Last updated
2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis Ankle, Osteoarthritis

Keywords

SPECT/CT, MRI, osteoarthritis, Foot and/or Ankle

Brief summary

The diagnose of symptomatic osteoarthritis in the ankle, mid- and hind foot remains challenging. There is no gold standard for the work-up and various hospitals use different protocols. Current literature shows a promising role for SPECT-CT imaging in ankle, hind- and midfoot OA. In a previous study investigating the role of SPECT-CT in a reproducible group we have observed a change in diagnosis in 53% when SPECT-CT data was added to the data of conventional workup alone. In 26% of patients addition of SPECT-CT data resulted in change of the original treatment plan. To our knowledge no prospective studies are available on this subject for both SPECT-CT and MRI. In our clinic both SPECT-CT and MRI are used in the work-up for patients with ankle, hind- and midfoot pain. Although we experience good result with SPECT-CT, MRI might be able to detect symptomatic OA as well. Moreover MRI provide more information about soft tissue and is less harmful for the patient in comparison to SPECT-CT. The aim of this study is to determine the diagnostic performance of SPECT-CT and MRI when used routinely in patients with symptomatic OA of the ankle, hind- and midfoot.

Detailed description

Objective: The objective is to determine diagnostic performance of SPECT-CT and MRI when used routinely in patients with symptomatic OA of the ankle, hind- and midfoot. Study design: Prospective cohort study. Study population: All patients ≥18years old, referred to the Martini Hospital Groningen department of Orthopedic surgery with suspected symptomatic osteoarthritis of the foot and ankle and rest pain of NRS ≥4. Main study parameters/endpoints: Main parameters will be the diagnostic performance (a.o. sensitivity and specificity, positive and negative predictive value)of SPECT-CT and MRI. The standard work up consist of questionnaires, detailed physical examination, conventional radiographic, MRI, SPECT-CT imaging and ultrasound guided injections. There are no additional risks for participating in this study compared to current standardised hospital workup.

Interventions

DIAGNOSTIC_TESTSPECT/CT

SPECT/CT of the foot and ankle

DIAGNOSTIC_TESTMRI

MRI of the foot and ankle

Sponsors

Martini Hospital Groningen
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Suspected symptomatic ankle, hind- or midfoot OA * Informed consent * Age ≥ 18 years * Average NRS ≥4 over the past week.

Exclusion criteria

* Contraindication for surgery * Contraindication for SPECT-CT or MRI * Contraindication for intra-articular injections * Isolated forefoot pathology * Fracture, ligamentous or tendon injury of the ankle, hind- and/or midfoot trauma within one year before presentation * History of neurological disease * History of foot and/or ankle surgery (affected side) * Inability to read and understand the written information

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic accuracy of SPECT/CT and MRI1 yearPrimary objective is to determine overall diagnostic performance (in terms of sensitivity + specificity, positive and negative predictive values, positive and negative likelihood ratios, and diagnostic odds ratio) of SPECT-CT and MRI for diagnosing symptomatic OA in the ankle, hind- and midfoot.

Countries

Netherlands

Contacts

CONTACTArthur van Hasselt, MD
a.vanHasselt@mzh.nl0031646345384
CONTACTAstrid de Vries, dr
A.deVries3@mzh.nl
PRINCIPAL_INVESTIGATORTom van Raaij, MD/PhD

Martini Ziekenhuis

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026